ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

First-line immunotherapy with anti-PD-1 antibody for extranodal NK/T-cell lymphoma: A retrospective study

Wang, Xiaoxiao; Wen, Lei; Liao, Jing; Feng, Yanfen; Li, Yuhong; Zhou, Zhaoming; Zhou, Cheng*; Huang, Huiqiang*南方医科大学; 中山大学
British Journal of Haematology2023-8DOI: 10.1111/bjh.18957
11阅读
引用收藏
分享

摘要

Anti-PD-1 antibody has shown certain effects in patients with newly diagnosed extranodal NK/T-cell lymphoma (ENKTL). Here, we evaluated the clinical efficacy and safety of first-line anti-PD-1 antibody for the treatment of patients with ENKTL and explored biomarkers for treatment response. The clinical data of 107 patients with newly diagnosed ENKTL were retrospectively analysed. Patients received either first-line anti-PD-1 antibody induction treatment or anti-PD-1 antibody combined with asparaginase-based chemotherapy (immunochemotherapy). We found that immunochemotherapy was an independent prognostic factor for longer PFS (p < 0.001). The overall response rate and complete remission rate of immunochemotherapy group was higher than immunotherapy induction group (86.11% vs. 62.86% and 72.22% vs. 52.29%, respectively, p = 0.013). We also observed pretreatment CD4/CD8 ratio >0.83 was significant associated with better response and longer PFS in ENKTL patients received first-line anti-PD1-antibody. Plasma copy number of EBV decreased more significantly in patients with CD4/CD8 ratio >0.83 after treatment. PD-L1 expression was associated with better response and PFS, while elevated plasma IL-6, IL-10 and IFN-? were associated with poor prognosis. Anti-PD-1 antibody treatment showed promising results in newly diagnosed ENKTL patients. The assessment of pretreatment CD4/CD8 ratio in ENKTL seems feasible for identifying responders to anti-PD-1 antibody treatment.

学科与关键词

关键词
anti-PD-1 antibodybiomarkerCD4/CD8 ratioENKTL
相关
加载中…
  • The emerging role of anti-PD-1 antibody-based regimens in the treatment of extranodal NK/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis
    He, Yanxia; Gao, Yan; Ping, Liqin; He, Haixia; Huang, Cheng; Bai, Bing; Wang, Xiaoxiao; Li, Zhiming; Cai, Qingqing; Huang, Yuhua; Pan, Xueyi; Zeng, Wenbin; Liu, Yanan; Huang, Huiqiang*Journal of Cancer Research and Clinical Oncology, 2023, 149(5): 2017-2027.被引 4
  • PD-1 Antibody (Sintilimab) Plus Histone Deacetylase Inhibitor (Chidamide) for the Treatment of Refractory or Relapsed Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (r/r ENKTL): Updates of the Phase Ib/II Scent Study
    Yan, Gao; Zhang, Liling; Li, Wenyu; Wei, Xu; Feng, Ru; Li, Xue-Ping; Chen, Yu; Wu, Huijing; Wang, Xiaoxiao; Bai, Bing; Huang, Huiqiang65th Annual Meeting of the American-Society-of-Hematology (ASH), San Diego, CA, 2023-12-09 To 2023-12-12.
  • CD56-Negative Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Study in 443 Patients Treated by Chemotherapy With or Without Asparaginase
    Yang, Jing; Li, Pengfei; Piao, Yingshi; Liu, Xindi; Wei, Liqiang; Sang, Wei*; Zhang, Luo*; Wang, Liang*Frontiers in Immunology, 2022, 13: 829366.被引 1
查看全部 →

发表信息

论文状态
公开发表
期刊
British Journal of Haematology
发表日期
2023-08
卷期
第 202 卷, 第 4 期
页码
812-824
DOI
10.1111/bjh.18957
语言
ENGLISH
成果收录
SCIE
资助标注
China Postdoctoral Science Foundation [2020T130052ZX, 2022M711507]; Medical Scientific Research Foundation of Guangdong Province [B2021203]; Science and Technology Program of Guangzhou [202002030445]

作者

  • W

    Wang, Xiaoxiao (第一作者)

    sun yat sen univ

  • W

    Wen, Lei

    sun yat sen univ

查看全部 8 位作者收起作者
  • L

    Liao, Jing

    southern med univ

  • F

    Feng, Yanfen

    sun yat sen univ

  • L

    Li, Yuhong

    sun yat sen univ

  • Z

    Zhou, Zhaoming

    southern med univ

  • Z

    Zhou, Cheng (通讯)

    southern med univ

  • H

    Huang, Huiqiang (通讯)

    sun yat sen univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417